MBAI Up On High Vol After Expanding Collab w/ Rejuvenation MedBright AI Investments Inc. (Ticker: MBAI.c or MBAIF for US investors) is trading in the green on the CSE on above-average volume after announcing the expansion of its groundbreaking artificial intelligence platform, MedMatrix, through a strategic collaboration with Rejuvenation, a leading dermatology group known for its excellence in advanced dermatological care.
This expansion highlights the scalability of MBAI's MedMatrix Platform within the massive 200 billion dollar addressable healthcare market. It also highlights the ability for MBAI to scale the deployment and number of users of their Medmatrix platform rapidly.
Despite MBAI's Market Cap being less than 22M they have already signed on 14 clinics within 2 months, including a Yale School of Medicine Affiliated Clinic Group.
Rejuvenation, with its extensive network of 8 clinics spanning across 3 provinces in Canada, has positioned itself as a key player in dermatological care. Boasting a highly skilled team comprising 21 dermatologists, 5 Mohs surgeons, 2 plastic surgeons, and 13 general practitioners specializing in dermatology, Rejuvenation is set to leverage MedMatrix for an expanded scope, particularly in the realms of cosmetic marketing and clinical trial analytics.
The addition of clinical trial recruitment tools to MedMatrix will empower Rejuvenation to swiftly assess patient eligibility for clinical trials. This not only improves patient access to cutting-edge treatments but also streamlines the clinical trial recruitment process for Rejuvenation’s partners.
Trevor Vieweg, the CEO of MedBright AI, expressed enthusiasm about the extended collaboration, stating, “We are excited to expand our work with Rejuvenation to further improve their already impressive operations in cosmetic treatment marketing and clinical trials. Combining the power of MedMatrix with the large patient base of Rejuvenation is set to provide new opportunities for Rejuvenation and improve the patient experience for their customers.”
As MedBright AI continues to allocate capital and invest strategically in healthcare technology, this collaboration underscores its commitment to fostering synergies and generating superior returns for shareholders.
The company remains focused on identifying significant, high-quality opportunities with strong return potentials while upholding a steadfast commitment to governance. MedBright AI's mission is clear – to construct a portfolio of investments that not only align with their strategic vision but also contribute to the advancement of healthcare technology on a global scale.
https://financialpost.com/globe-newswire/medbright-ais-medmatrix-to-expand-its-ai-offerings-for-cosmetic-marketing-clinical-trial-analytics
Posted on behalf of Medbright AI Investments Inc.